Roche’s Genentech agreed a discovery and development collaboration with Earendil Labs focused on oncology bispecific antibodies. Earendil will receive a $55 million upfront payment, with milestones potentially pushing the deal value above $1.5 billion. The partnership continues Genentech’s active search for next-generation antibody formats and builds on its recent expansion in dealmaking for oncology assets. For Earendil, the pact provides non-dilutive funding to advance candidate discovery programs toward preclinical and clinical development. Deal size and oncology focus highlight how bispecific platforms remain a priority battlefield for large pharma seeking differentiated antibody therapies.